Flagging high-risk individuals with a ML model improves NSCLC early detection in a USPSTF-eligible population

Eran N. Choman¹, Alon Lanyado¹, Prof. Michael K. Gould, MD, MS²

Background

The USPSTF recommends annual lung cancer screening with LDCT in adults aged 50 to 80 years who have a ≥20 pack-year smoking history and currently smoke or have quit within the past 15 years. Risk prediction models are an alternative approach to identify high-risk individuals for screening that may have advantages compared to age and smoking history-based selection. We compared the performance of two risk prediction models, LungFlag and adapted to EHR data PLCOm2012 (mPLCOm2012).

Methods

Data from a large US health system including 6,505 case patients with non-small cell lung cancer (NSCLC) and 189,597 contemporaneous NSCLC-free controls were used to evaluate the performance of an optimized version of a previously published machine-learning model (LungFlag) to detect NSCLC among individuals who meet the USPSTF criteria compared to the performance of mPLCOm2012. The model used existing routine out-patient lab measurements, smoking history, comorbidities, and demographic data.

Results

Data were analyzed using the area under the receiver operating characteristic curve (AUC), and diagnostic sensitivity on the USPSTF screen-eligible population (Tables 1-3) and Ever Smokers ages 50-80 population (Table 4). The risk predictor was calculated for a 3-12-month window prior to the diagnosis date (Dx) using cut-offs yielding specificity levels of 97%, 95% or 90%.

Conclusion

By using available information existed in the EHR, the LungFlag model was more accurate for early diagnosis of NSCLC than mPLCOm2012, demonstrating the potential to help prevent lung cancer deaths through early detection among the subgroup of USPSTF as well as the Ever Smokers population.

Contact

Eran N Choman
eran@earlysign.com
+972 52 5611154
www.earlysign.com





Tabla 1. All	NSCLC USPSTE	Eligibla
Iable I. All	INOULU UOFOTI	

			Sensitivity @ Specificity Level					
NSCLC	AUC		Sens @ 97% Spec		Sens @ 95% Spec		Sens @ 90% Spec	
Stage	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012
Stage 0	0.840*	0.770	26.5	23.5	44.1*	23.5	55.9*	35.3
(in situ)	[0.770,0.890]	[0.710,0.850]	[11.5,46.3]	[10.0,38.7]	[26.7,61.3]	[10.3,41.2]	[37.9,69.7]	[18.8,53.1]
Stage I	0.793*	0.747	21.4*	11.0	28.5*	16.7	42.7*	31.7
	[0.770,0.822]	[0.722,0.775]	[16.8,26.6]	[7.4,15.2]	[24.1,35.2]	[12.6,21.9]	[38.3,49.7]	[25.5,37.2]
Stage II	0.824*	0.764	26.6	18.8	32.0	25.0	44.5*	33.6
	[0.785,0.852]	[0.729,0.808]	[18.1,34.7]	[12.7,26.5]	[24.0,41.3]	[17.6,33.8]	[35.7,54.6]	[25.7,42.4]
Stage III	0.777*	0.739	16.7	15.9	24.7	18.8	40.2	33.1
	[0.746,0.805]	[0.709,0.770]	[11.2,21.2]	[11.2,20.6]	[18.5,29.6]	[13.9,24.0]	[32.6,45.8]	[26.5,39.0]
Stage IV	0.753*	0.726	15.5*	11.7	21.7	17.4	33.1	29.1
	[0.733,0.775]	[0.704,0.748]	[12.2,19.1]	[9.0,14.9]	[17.3,25.4]	[12.8,21.3]	[28.1,38.0]	[24.1,33.0]
Total	0.772*	0.735	17.7*	12.1	23.7*	18.0	37.5*	29.5
	[0.757,0.788]	[0.718,0.749]	[15.2,20.5]	[9.6,14.1]	[21.2,26.8]	[14.7,20.3]	[33.6,40.5]	[26.5,33.2]

^{*} Statistically significant difference (P-value<0.05)

Table 2: Adenocarcinoma NSCLC USPSTF Eligible

			Sensitivity @ Specificity Level					
NSCLC	AUC		Sens @ 97% Spec		Sens @ 95% Spec		Sens @ 90% Spec	
Stage	LungFlag	mPLC0m2012	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012
Stage 0	0.900*	0.770	33.3	0.0	66.7*	0.0	83.3*	0.0
(in situ)	[0.780,0.980]	[0.710,0.850]	[0.0,83.3]	[0.0,0.0]	[16.7,100.0]	[0.0,0.0]	[37.5,100.0]	[0.0,0.0]
Stage I	0.783*	0.747	17.9*	6.9	25.5*	12.4	41.4*	24.8
	[0.751,0.814]	[0.722,0.775]	[12.6,25.7]	[3.2,11.9]	[17.1,31.3]	[8.5,19.9]	[31.8,46.2]	[17.8,33.6]
Stage II	0.780	0.764	22.7*	6.8	25.0	13.6	38.6*	15.9
	[0.720,0.830]	[0.729,0.808]	[7.3,31.2]	[0.0,17.2]	[11.5,35.1]	[4.3,22.6]	[19.5,46.5]	[6.5,26.8]
Stage III	0.749	0.739	11.8	10.5	18.4	11.8	34.2	25.0
	[0.704,0.801]	[0.709,0.770]	[5.7,21.3]	[4.0,17.9]	[11.3,29.9]	[5.6,21.3]	[23.8,45.0]	[14.3,32.9]
Stage IV	0.737	0.726	14.4*	8.5	19.9*	13.1	30.5*	25.0
	[0.705,0.766]	[0.704,0.748]	[9.6,19.0]	[4.8,11.8]	[14.3,24.4]	[8.2,17.1]	[25.0,37.3]	[18.9,29.7]
Total	0.754*	0.707	15.7*	8.1	20.4*	13.2	33.8*	24.2
	[0.733,0.775]	[0.685,0.731]	[12.0,18.8]	[5.8,11.0]	[17.1,25.5]	[9.7,16.5]	[28.4,37.9]	[20.2,28.5]

^{*} Statistically significant difference (P-value<0.05)

Table 3: Squamous NSCLC USPSTF Eligible

			Sensitivity @ Specificity Level					
NSCLC	AUC		Sens @ 97% Spec		Sens @ 95% Spec		Sens @ 90% Spec	
Stage	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012
Stage 0	0.820	0.790	21.4	28.6	28.6	28.6	35.7	35.7
(in situ)	[0.720,0.900]	[0.680,0.880]	[0.0,41.7]	[7.1,55.6]	[6.2,53.8]	[10.0,60.0]	[12.5,66.7]	[12.5,64.3]
Stage I	0.838*	0.784	25.8	13.4	34.0*	21.6	50.5*	39.2
	[0.790,0.867]	[0.745,0.821]	[17.4,34.8]	[7.0,20.8]	[25.5,44.9]	[14.0,30.2]	[40.0,59.8]	[31.5,51.4]
Stage II	0.847*	0.803	23.0	26.2	31.1	32.8	49.2	41.0
	[0.808,0.887]	[0.755,0.851]	[15.4,39.0]	[15.4,37.1]	[20.8,43.1]	[22.1,47.1]	[35.2,60.9]	[30.9,53.6]
Stage III	0.794*	0.749	18.3	17.4	24.3	21.7	41.7	34.8
	[0.750,0.824]	[0.701,0.790]	[10.5,24.5]	[10.3,24.5]	[17.0,33.7]	[13.6,29.8]	[31.0,49.5]	[25.5,44.1]
Stage IV	0.778	0.763	18.7	13.8	24.4	22.8	36.6	31.7
	[0.740,0.819]	[0.725,0.802]	[11.2,25.2]	[8.3,20.8]	[16.2,32.8]	[14.7,30.8]	[26.7,44.8]	[24.2,40.9]
Total	0.802*	0.767	20.3*	15.0	28.2*	22.0	43.2*	36.4
	[0.783,0.829]	[0.742,0.792]	[16.7,26.2]	[11.0,19.1]	[23.5,32.8]	[17.8,27.2]	[37.4,48.4]	[31.6,41.6]

^{*} Statistically significant difference (P-value<0.05)

Table 4: All NSCLC Ever Smokers Ages 50-80

				.90000				
				l				
NSCLC Stage	AUC		Sens @ 97% Spec		Sens @ 95% Spec		Sens @ 90% Spec	
	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012	LungFlag	mPLCOm2012
Stages 0-II	0.851* [0.839,0.863]	0.817 [0.805,0.830]	32.5* [29.3,35.8]	23.5 [20.9,26.3]	42.2* [39.2,45.5]	31.3 [28.4,34.2]	58.1* [55.2,61.1]	47.8 [44.7,51.3]
Stages III-IV	0.824* [0.815,0.833]	0.796 [0.786,0.806]	23.5* [21.5,25.6]	20.1 [18.2,22.2]	33.9* [31.5,36.4]	28.6 [26.3,30.8]	51.0* [48.3,53.6]	42.7 [40.4,45.0]
Total	0.831* [0.823,0.839]	0.802 [0.794,0.809]	26.1* [24.4,27.9]	21.0 [19.4,22.7]	36.2* [34.2,38.3]	29.4 [27.7,31.3]	52.8* [50.7,55.0]	44.1 [42.2,46.1]

^{*} Statistically significant difference (P-value<0.05)

¹ Medial EarlySign, Hod Hasharon, Israel.

² Department of Health Systems Science, KAISER PERMANENTE BERNARD J. TYSON SCHOOL OF MEDICINE, CA, USA.